Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR12169(B)] to RD3
- Suitable for: WB
- Reacts with: Mouse, Rat
Product nameAnti-RD3 antibody [EPR12169(B)]
See all RD3 primary antibodies
DescriptionRabbit monoclonal [EPR12169(B)] to RD3
Tested applicationsSuitable for: WBmore details
Unsuitable for: ICC/IF,IHC or IP
Species reactivityReacts with: Mouse, Rat
Does not react with: Human
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human RD3 aa 100 to the C-terminus (Cysteine residue). The exact sequence is proprietary.
Database link: Q7Z3Z2
- Mouse eyeball lysate, Rat eyeball lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab171946 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Predicted molecular weight: 23 kDa.|
RelevanceRD3 is preferentially expressed in retina. Defects in RD3 are the cause of Leber congenital amaurosis type 12 (LCA12).
- C1orf36 antibody
- chromosome 1 open reading frame 36 antibody
- LCA12 antibody
ab171946 has not yet been referenced specifically in any publications.